Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Expenses (2016 - 2025)

Agios Pharmaceuticals' Operating Expenses history spans 14 years, with the latest figure at $141.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 4.26% year-over-year to $141.5 million; the TTM value through Dec 2025 reached $526.2 million, up 13.83%, while the annual FY2025 figure was $526.2 million, 13.83% up from the prior year.
  • Operating Expenses reached $141.5 million in Q4 2025 per AGIO's latest filing, up from $129.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $141.5 million in Q4 2025 to a low of $91.2 million in Q3 2021.
  • Average Operating Expenses over 5 years is $109.4 million, with a median of $104.2 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: grew 22.85% in 2021, then fell 5.64% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $104.8 million in 2021, then decreased by 1.28% to $103.5 million in 2022, then increased by 9.56% to $113.4 million in 2023, then grew by 19.75% to $135.8 million in 2024, then grew by 4.26% to $141.5 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Operating Expenses are $141.5 million (Q4 2025), $129.7 million (Q3 2025), and $139.5 million (Q2 2025).